While GLP-1 receptor agonists and bariatric surgery offer significant metabolic benefits, experts caution that rapid weight ...

A study has found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-cancer benefits that extend beyond ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

GLP-1 drugs achieve some of these effects by directly affecting the brain’s cravings for food, and that might also extend to ...

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

Data from a Swedish clinic suggests that GLP-1 drugs can be effective in managing severe obesity in children, offering a ...

In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...

A new analysis being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...